Portal de Periódicos da CAPES

Dolutegravir Resistance in Malawi’s National HIV Treatment Program

2022; Oxford University Press; Volume: 9; Issue: 5 Linguagem: Inglês

10.1093/ofid/ofac148

2328-8957

Joep J. van Oosterhout, Chifundo Chipungu, Lyse Nkhoma, Hope Kanise, Mina C. Hosseinipour, Jean Babtiste Sagno, Katherine Simon, Carrie M. Cox, Risa M. Hoffman, Kim Steegen, Bilaal W Matola, Sam Phiri, Andreas Jahn, Rose Nyirenda, Tom Heller,

HIV Research and Treatment

Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020-September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.